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Abstract
Purpose: To investigate the optimal contact time and concentration for viricidal ac-
tivity of oral preparation of povidone-iodine (PVP-I) against SARS-CoV-2 (‘corona
virus’) to mitigate the risk and transmission of the virus in the dental practice.
Materials and Methods: The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) USA-WA1/2020 strain, virus stock was tested against oral antiseptic
solutions consisting of aqueous povidone-iodine (PVP-I) as the sole active ingredient.
The PVP-I was tested at diluted concentrations of 0.5%, 1%, and 1.5%. Test media
without any virus was added to 2 tubes of the compounds to serve as toxicity and
neutralization controls. Ethanol (70%) was tested in parallel as a positive control, and
water only as a negative control. The test solutions and virus were incubated at room
temperature (22 ± 2 °C) for time periods of 15 and 30 seconds. The solution was
then neutralized by a 1/10 dilution in minimum essential medium (MEM) 2% fetal
bovine serum (FBS), 50 µg/mL gentamicin. Surviving virus from each sample was
quantified by standard end-point dilution assay and the log reduction value (LRV) of
each compound compared to the negative (water) control was calculated.
Results: PVP-I oral antiseptics at all tested concentrations of 0.5%, 1%, and 1.5%,
completely inactivated SARS-CoV-2 within 15 seconds of contact. The 70% ethanol
control group was unable to completely inactivate SARS-CoV-2 after 15 seconds of
contact, but was able to inactivate the virus at 30 seconds of contact.
Conclusions: PVP-I oral antiseptic preparations rapidly inactivated SARS-CoV-
2 virus in vitro. The viricidal activity was present at the lowest concentration of
0.5 % PVP-I and at the lowest contact time of 15 seconds. This important finding
can justify the use of preprocedural oral rinsing with PVP-I (for patients and health
care providers) may be useful as an adjunct to personal protective equipment, for
dental and surgical specialties during the COVID-19 pandemic.
Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2 the virus resulting in the corona virus disease 2019,
COVID-19) is a novel coronavirus in the same family as the
severe acute respiratory syndrome (SARS) and middle east
respiratory syndrome (MERS) viruses that emerged in local
outbreaks in 2003 and 2015. From the first cases recognized
in late December 2019 by health care workers in China,
it has rapidly spread across the globe.1 The World health
organization (WHO) declared the spread of COVID-19 a
global pandemic on March 11, 2020. This has significantly
changed the way that dentistry is practiced around the world.
The clinical workflow of dentists, especially prosthodontists,
has been significantly altered due to the fact that the viral load
is highest in the nasal cavity, nasopharynx and oropharynx
related to the high expression of ACE2 receptor on goblet cells
and respiratory epithelium used as fist entry into the body by
SARS-CoV-2.2,3 Viral shedding can be detected from nasal
swabs before, during and after the onset of acute symptomatic
disease including in seropositive antibody-converted conva-
lescent cases.2,3 As the mouth is also part of the oropharynx,
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it harbors bacteria and viruses from the nose, throat and the
respiratory tract and contaminated saliva can easily result in
spread of viral infections.4,5
In a dental setting, well recognized terms related to microbi-
ological risk are aerosol and splatter.4-7 Aerosols are generally
defined as suspension of fine solid particles or liquid droplets
in air and splatters are larger liquid particles in air that impact
a surface and then break apart. In dentistry, aerosols are rec-
ognized as airborne particles smaller than 50 µm in diameter
which are small enough to stay in air for extended periods and
entail risk of environmental contamination, and entry into res-
piratory tracts.4-7 On the other hand, splatters are denoted as
airborne particles larger than 50 µm in diameter and too large
to stay suspended in air for longer periods. Splatters are typ-
ically seen as droplets ejected forcefully in a ballistic manner
similar to a bullet until they contact a surface.4-7 Any dental
procedure that can aerosolize contaminated saliva can signifi-
cantly increase airborne contamination with microorganisms.7
Most procedures in contemporary prosthodontics ranging from
single unit restorations to complex implant surgery include
aerosol production due to the use of handpieces and air-water
syringes. Additional dental maintenance procedures involving
the use of ultrasonic scalers and air abrasion units produce even
higher visible aerosols.4 All these procedures involve aerosol
production resulting in higher risk for clinicians, dental assis-
tants, and patients.
Due to the COVID-19 pandemic which has resulted in sig-
nificant morbidity and mortality, it is imperative for clinicians
to consider adjunctive protective measures that can add an ad-
ditional barrier of safety in providing prosthodontics treatment.
Understandably, there is no single method or agent, which can
completely eliminate or minimize the risk of COVID-19 infec-
tion to dental personnel and other patients. Harrel and Molinari
have described 3 layers of defense against aerosols in a dental
office.4 The first layer is personal protective equipment (PPE)
such as gloves, eye glasses and masks. The second layer is reg-
ular use of oral antiseptic rinse and the third layer is the use
of high volume evacuator (HEV) (“high speed suction”) and
adjunctive high efficiency particulate air (HEPA) filters. The
first and third layers of defense have received significant atten-
tion by dentists however, the second layer of defense has not
received sufficient attention.
Harrel and Molinari recommended preprocedural oral rins-
ing with chlorhexidine gluconate a rinse with essential oils,
but both of these are known to only be efficacious against
bacteria, with no viricidal properties.4 Therefore, the Ameri-
can Dental Association (ADA) interim guidelines from April
2020 have suggested preprocedural oral rinsing with 1.5% hy-
drogen peroxide (commercially available in the United States)
or 0.2% povidone-iodine PVP-I (not commercially available
in the United States).8 The Centers for Disease Control and
Prevention (CDC) have also recommended preprocedural rins-
ing with antimicrobial rinses such as chlorhexidine gluconate,
essential oils, PVP-I or cetylpyridinium chloride.9 Presently,
there are no clinical studies supporting the viricidal effects
of any pre-procedural oral rinse against SARS-CoV-2.8 Ad-
ditionally, there are no in vitro studies on the viricidal effect of
the commercially available 1.5% hydrogen peroxide. However,
PVP-I solutions of 0.23% have effectively inactivated SARS-
CoV and MERS with contact times as low as 15 seconds in
vitro.10,11 The SARS-CoV-2 virus resulting in the COVID-19
pandemic is a novel coronavirus in the same family and is ex-
pected to be inactivated by PVP-I in the same manner.
Therefore, the purpose of this study was to investigate the
optimal contact time and concentration for viricidal activity
of oral preparation of povidone-iodine (PVP-I) against SARS-
CoV-2 (‘corona virus’) to mitigate the risk and transmission of
the virus in the dental practice. The null hypothesis was that
there would be no difference in viricidal activity of PVP-I at
various concentrations and contact times as well as there would
be no difference between PVP-I and the positive and negative
controls.
Materials and methods
All laboratory work with SARS-CoV-2 was conducted in
biosafety level 3 (BSL-3) laboratories at The Institute for An-
tiviral Research at Utah State University Logan, UT follow-
ing established standard operating procedures approved by
the Utah State University Biohazards Committee. The SARS-
CoV-2, USA-WA1/2020 strain, virus stock was prepared prior
to testing by growing in Vero 76 cells. Culture media for
prepared stock (test media) was minimum essential medium
(MEM) with 2% fetal bovine serum (FBS) and 50 µg/mL gen-
tamicin. The oral rinse antiseptic solution consisted of various
concentrations of aqueous povidone-iodine (PVP-I) as the sole
active ingredient (Veloce BioPharma; Fort Lauderdale, FL).
The PVP-I concentrations of each solution as supplied and af-
ter 1:1 dilution are listed in Table 1.
The test compounds were mixed directly with virus solution
so that the final concentration was 50% of each individual test
compound and 50% virus solution. A single concentration was
tested in triplicate. Test media without virus was added to 2
tubes of the compounds to serve as toxicity and neutralization
controls. Ethanol (70%) was tested in parallel as a positive con-
trol and water only as a virus control. The test solutions and
virus were incubated at room temperature (22 ± 2 °C) for 15
and 30 seconds. The solution was then neutralized by a 1/10
dilution in MEM 2% FBS, 50 µg/mL gentamicin.
Surviving virus from each sample was quantified by standard
end-point dilution assay. The neutralized samples were pooled
and serially diluted using eight log dilutions in test medium.
Then 100 µL of each dilution was plated into quadruplicate
wells of 96-well plates containing 80% to 90% confluent Vero
76 cells. The toxicity controls were added to additional 4 wells
of Vero 76 cells and 2 of those wells at each dilution were
infected with virus to serve as neutralization controls, ensur-
ing that residual sample in the titer assay plate did not inhibit
growth and detection of surviving virus. Plates were incubated
at 37 ± 2 °C with 5% CO2 for 5 days. Each well was then
scored for presence or absence of infectious virus. The titers
were measured using a standard endpoint dilution 50% cell
culture infectious dose (CCID50) assay calculated using the
Reed-Muench equation and the log reduction value (LRV) of
each compound compared to the negative (water) control was
calculated.12
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Table 1 Virus titers and log reduction value of SARS-CoV-2 when incubated with various concentrations of PVP-I and the controls for 15 seconds.
Each experimental sample was tested 3 times and average virus titers are reported




PVP-I 3.0% Oral Rinse Antiseptic 1.5 15 <0.67 3.0
PVP-I 1.5% Oral Rinse Antiseptic 0.75 15 <0.67 3.0
PVP-I 1.0% Oral Rinse Antiseptic 0.5 15 <0.67 3.0
Ethanol 70% N/A 15 1.5 2.17
Water N/A 15 3.67 N/A
aLog10 CCID50 of virus per 0.1 mL. The assay lower limit of detection is 0.67 Log10 CCID50/0.1 mL.
bLRV (log reduction value) is the reduction of virus compared to the virus control.
Table 2 Virus titers and log reduction value of SARS-CoV-2 when incubated with various concentrations of PVP-I and the controls for 30 seconds.
Each experimental sample was tested 3 times and average virus titers are reported




PVP-I (3.0%) Oral Rinse Antiseptic 1.5 30 <0.67 3.33
PVP-I (1.5%) Oral Rinse Antiseptic 0.75 30 <0.67 3.33
PVP-I (1.0%) Oral Rinse Antiseptic 0.5 30 <0.67 3.33
Ethanol 70% N/A 30 <0.67 3.33
Water N/A 30 4.0 N/A
aLog10 CCID50 of virus per 0.1 mL. The assay lower limit of detection is 0.67 Log10 CCID50/0.1 mL.
bLRV (log reduction value) is the reduction of virus compared to the virus control.
Results
Virus titers and LRV of SARS-CoV-2 when incubated with
various concentrations of the manufacturer’s compounds for
15 seconds are shown in Table 1. After the 15-second con-
tact time, all of the PVP-I oral rinse antiseptics tested were
effective at reducing >3 log10 CCID50 infectious virus from,
3.67 log10 CCID50/0.1 mL to 0.67 log10 CCID50/0.1 mL or
less. Table 2 shows the virus titers and LRV of SARS-CoV-2
when the virus was incubated for 30 seconds with each of the
test compounds at 50/50 ratio. For the 30-second contact time,
once again all of the PVP-I oral rinse antiseptics tested were ef-
fective at reducing >3.33 log10 CCID50 infectious virus from,
4.0 log10 CCID50/0.1 mL to 0.67 log10 CCID50/0.1 mL or
less. No cytotoxicity was observed with any of the test com-
pounds. The positive control and neutralization controls per-
formed as expected.
Discussion
The purpose of this study was to investigate the optimal contact
time and concentration for viricidal activity of oral preparation
of povidone-iodine (PVP-I) against SARS-CoV-2 (‘corona
virus’) to mitigate the risk and transmission of the virus in the
dental practice. Data from this in vitro study rejected the null
hypothesis, and showed the rapid viricidal activity of PVP-
I oral formulation. The minimum 15 seconds contact time
proved to be sufficient for PVP-I. This is similar to the re-
sults from previous studies where PVP-I solutions of 0.23%
inactivated SARS-CoV and MERS with contact times as low
as 15 seconds in vitro.10,11 Oral decontamination is an impor-
tant adjuvant process along with PPE to reduce viral trans-
mission among dental patients especially during aerosol gen-
erating procedures. A majority of prosthodontic procedures
involve close physical contact with the patient and generate
aerosols increasing the risk of viral transmission. In the ab-
sence of clinical studies, the residual challenge in oral antisep-
sis is to find the effective concentration and duration of topi-
cal preparations which are safe to administer. Several different
protocols have been used anecdotally to dilute PVP-I at a vary-
ing concentration ranging from 0.25% to 0.5% in an attempt to
inactivate the virus from the nasal and oral cavity.13
Oral use of PVP-I antiseptic rinse is not novel to
dentistry and has been used effectively in the past for
oral decontamination,14 periodontal therapy,15 peri-implant
therapy16 and post-extraction therapy.17 PVP-I has proven safe
for use in the oral cavity up to 5% concentration and nasal cav-
ities at concentrations up to 1.25%.18-20 At these concentra-
tions, no change in olfaction or mucociliary clearance has been
noted.21 Thyroid stimulating hormone was shown to slightly
increase within normal levels after oral use of 5% PVP-I for 6
months, but no clinical thyroid disease was detected.22 Nev-
ertheless, at concentrations of 0.2% to 0.5% iodine absorp-
tion is minimal and below the total daily iodine intake for a
healthy adult of 150 µg. Additionally, no change in taste or
discoloration of teeth has been reported in the literature.23 The
substantivity (prolonged association between a topical mate-
rial and a substrate) of oral PVP-I antiseptic rinse has been re-
ported to be as long as 4 hours.24 However PVP-I solutions are
contraindicated for patients with anaphylactic allergy to iodine,
pregnancy, active thyroid disease, and patients undergoing ra-
dioactive iodine therapy.25-27
The alternative to oral PVP-I solution is 1.5% hydrogen per-
oxide rinse, as recommended by the ADA interim guidelines.8
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Presently the CDC does not recommend this rinse due to ab-
sence of sufficient scientific evidence.9 Though 1.5% hydrogen
peroxide is known to be antibacterial, it is chemically more un-
stable. There are no published studies showing the inactivation
of SARS-CoV-2 by this solution at 1 minute contact period.28
The potential oral toxicity of routine use of this solution for
1 minute as well as its substantivity is unknown at this time.
Additionally, alcohol is present in most oral rinses and results
from this study showed that it required a longer time for viral
inactivation than PVP-I oral solutions tested.
Some disadvantages of the PVP-I oral solutions include the
absence of clinical research such as randomized clinical tri-
als, and the current absence of commercially available for-
mulation at lower concentrations for intra-oral use. Therefore,
dentists are required to dilute the commercially available an-
tiseptic formulation of 10% PVP-I, by 1:20, utilizing 0.5 ccs
of 10% povidone iodine and 9.5 ccs of sterile water for rou-
tine clinical use at 0.5%. This compound typically contains
suds which do not cause any adverse effects for topical usage.
However, dentists should make freshly diluted solutions each
day and refrigerate them during the day as diluted PVP-I so-
lutions are chemically unstable with respect to disproportiona-
tion into constituent equilibrium species. As the aqueous con-
centration of PVP-I decreases from 10% to less than 1%, these
solutions become unstable with respect to temperature, counte-
rions, commercial packaging and pH value. In order to ensure
that a diluted solution is safe for administration to the oral or
nasal cavity, there should either be an analysis of the chemi-
cal ingredients of each freshly-prepared solution or commer-
cial preparations of PVP-I at the appropriate dose (if available)
should be used.
Conclusions
PVP-I oral antiseptic preparations rapidly inactivated SARS-
CoV-2 virus in vitro. The 70% ethanol control group was un-
able to completely inactivate SARS-CoV-2 after 15 seconds of
contact, but was able to inactivate the virus at 30 seconds of
contact. The viricidal activity of PVP-I oral antiseptic solution
was present at the lowest concentration of 0.5 %, and at the
lowest contact time of 15 seconds. This important finding war-
rants the use of preprocedural oral rinsing with 0.5% PVP-I for
patients and health care providers. This solution serves as an
adjunct to personal protective equipment for dental and surgi-
cal specialties during the COVID-19 pandemic.
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